RedHill Biopharma Ltd. (RDHL)
Stock Price:
$8.10 USD
-0.27 (-3.23%)
Updated Aug 14, 2020 12:17 PM EDT - Market open
Key Info
| Market Cap |
285.68M |
| Revenue (ttm) |
5.61M |
| Net Income (ttm) |
-42.30M |
| Shares Out |
35.27M |
| EPS (ttm) |
-1.58 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$8.10 |
| Previous Close |
$8.37 |
| Change ($) |
-0.27 |
| Change (%) |
-3.23% |
| Day's Open |
8.37 |
| Day's Range |
7.93 - 8.40 |
| Day's Volume |
239,435 |
| 52-Week Range |
3.26 - 10.17 |
More Stats
| Market Cap |
285.68M |
| Enterprise Value |
241.63M |
| Earnings Date (est) |
Nov 16, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
35.27M |
| Float |
20.84M |
| EPS (basic) |
-1.4 |
| EPS (diluted) |
-1.58 |
| FCF / Share |
-1.44 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.80M |
| Short Ratio |
7.02 |
| Short % of Float |
n/a |
| Beta |
1.78 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
50.92 |
| PB Ratio |
7.25 |
| Revenue |
5.61M |
| Operating Income |
-43.20M |
| Net Income |
-42.30M |
| Free Cash Flow |
-40.92M |
| Net Cash |
44.06M |
| Net Cash / Share |
1.25 |
| Gross Margin |
71.87% |
| Operating Margin |
-770.07% |
| Profit Margin |
-672.50% |
| FCF Margin |
-729.36% |
| ROA |
-31.12% |
| ROE |
-115.97% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$20.50*
(153.09% upside)
Low
16.0
Current: $8.10
High
27.0
Target: 20.50
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 6.29 | 8.36 | 4.01 | 0.10 | - | 7.01 | 0.01 | 0.02 | 0.02 | - |
| Revenue Growth | -24.75% | 108.63% | 3867.33% | 3266.67% | -99.96% | 58350% | -25% | -30.43% | - | - |
| Gross Profit | 4.03 | 5.52 | 1.88 | 0.10 | - | 5.96 | 0.01 | 0.02 | 0.02 | - |
| Operating Income | -43.20 | -39.33 | -51.13 | -30.54 | -21.90 | -10.65 | -10.77 | -9.04 | -7.87 | -1.25 |
| Net Income | -42.30 | -38.82 | -45.54 | -29.37 | -21.09 | -10.71 | -10.63 | -10.33 | -15.50 | -2.54 |
| Shares Outstanding | 284 | 213 | 171 | 127 | 87.88 | 64.40 | 52.99 | 52.99 | - | - |
| Earnings Per Share | -1.40 | -1.70 | -2.60 | -2.40 | -1.90 | -1.30 | -1.70 | -2.00 | -3.20 | -2.70 |
| Operating Cash Flow | -40.75 | -34.46 | -44.77 | -28.26 | -17.83 | -12.23 | -8.44 | -6.80 | -4.69 | -1.63 |
| Capital Expenditures | -0.17 | -0.02 | -0.15 | -0.09 | -0.01 | -0.07 | -0.01 | -0.01 | -0.14 | -0.01 |
| Free Cash Flow | -40.92 | -34.49 | -44.92 | -28.34 | -17.84 | -12.30 | -8.45 | -6.80 | -4.83 | -1.64 |
| Cash & Equivalents | 47.87 | 53.19 | 46.21 | 66.15 | 58.14 | 22.95 | 12.11 | 18.37 | 18.65 | 9.15 |
| Total Debt | 3.82 | - | - | - | - | - | - | - | - | 11.25 |
| Net Cash / Debt | 44.06 | 53.19 | 46.21 | 66.15 | 58.14 | 22.95 | 12.11 | 18.37 | 18.65 | -2.09 |
| Assets | 74.10 | 62.41 | 57.34 | 74.21 | 66.83 | 28.86 | 14.34 | 20.10 | 20.19 | 10.51 |
| Liabilities | 14.10 | 11.23 | 12.28 | 11.51 | 6.75 | 3.85 | 2.42 | 1.08 | 1.40 | 12.10 |
| Book Value | 60.00 | 51.19 | 45.07 | 62.70 | 60.08 | 25.01 | 11.93 | 19.02 | 18.79 | -1.59 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
RedHill Biopharma Ltd. |
| Country |
Israel |
| Employees |
155 |
| CEO |
Dror Ben-Asher |
Stock Information
| Ticker Symbol |
RDHL |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: RDHL |
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of drugs for gastrointestinal diseases. The company promotes various gastrointestinal drugs, including Movantik for opioid-induced constipation in adults; Talicia for the treatment of Helicobacter pylori bacterial infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its late-stage clinical development programs include RHB-104, which is in Phase 3 study for treating Crohn's disease; RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) that is in first Phase 3 study to treat acute gastroenteritis and gastritis, as well as has completed Phase 2 study for treating irritable bowel syndrome with diarrhea; RHB-106, which is in planned Phase 2/3 studies for bowel preparation; ABC294640 (Yeliva), a SK2 selective inhibitor, which is in Phase 1/2a study for treating cholangiocarcinoma, as well as in Phase 2 study for prostate cancer; and RHB-107 that is in planned pilot study for cholangiocarcinoma, as well as has completed Phase 2 study for gastrointestinal and other solid tumors. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.